Abstract:ID 96214 Poster Board 484 Statement of the Problem . Epilepsy is the 4 th common neurological disorder after Parkinson's and Alzheimer's Disease and Stroke, with 3 million people in the US and 65 million people worldwide living with epilepsy. At the molecular level, it is known that voltage-gated sodium (VGSC) and calcium channels are related to the onset of seizures. Our lab engages in early drug design and discovery of novel small molecules as potential anti-seizure analogs, for epilepsy. Previous hit-to-lead optimization and target identification studies performed by our research team, led to the discovery of lead compound, ETSP 518001.This analog has been shown to act as a potent and selective Ca v 3.2 and Ca v 3.3 T-type voltage-gated calcium channel (T-VGCC) inhibitor. The objective of the work presented is to evaluate the inhibitory effects of several novel enaminone derivatives based on the prototype ETSP 518001 to identify new lead compounds as T-VGCC inhibitors. Methods: To design the novel enaminone derivatives, we utilized MedChem Studio, a simulation program to determine the druggability of the desired small molecules. Preliminary in vitro whole cell patch clamp experiments were performed to assess the inhibitory effects of several target analogs on voltage-activated Ca 2+ currents in human embryonic kidney (HEK-293) cells. Cav3.2 transfected HEK 293 cells were treated with 50 μM of test compounds and compared to the control group (none pretreated HEK 293 cells). Statistical analyses consisted of t-test for pairwise comparisons or one-way ANOVA followed by post hoc analysis using Tukey's honest significant difference test for comparisons between multiple groups. To validate the biological activity, studies were conducted at the National Institutes of Neurological Disorders and Stroke Epilepsy Therapy Screening Program, NIH. ETSP 578001 was investigated in acute rodent seizure models, to determine the efficacy and safety as an anti-seizure agent. Results. Each enaminone analog in our novel series were examined in MedChem studio and were calculated to have an average CLogP value of 2.96, and predicted to have high blood brain barrier permeability (99%). Preliminary in vitro studies showed ETSP 578001 has ≥ 90% inhibition of T-VGCC current, generated by the Ca v 3.2 subunit. Enaminone analog RHB62 caused a reduction in the Ca 2+ current, with lower potency than ETSP 578001. No inhibitory effect was shown at a similar concentration for analogs RHB59, RHB95 or RHB103. Further research showed that ETSP 578001 analog also inhibited VGSCs and had no effect on cell viability. These results show that ETSP 578001 had dual inhibition properties. Results from the preclinical in vivo study demonstrated that compound ETSP 587001 had low efficacy in the 6Hz 44 mA and the maximal electroshock (MES) rodent seizure model, as 0/4 animals were protected at pretreatment times 0.5h and 2h. Conclusion: A target-based drug design strategy was employed, that led to the discovery of ETSP 578001, as a dual VGSC and T-VGCC blocker. This analog showed toxicity in the ETSP rodent seizure model. Future studies will involve lead optimization and target identification studies on ETSP 578001. PhRMA Foundation, Pre-Doctoral Fellowship in Drug Discovvery University of Maryland Eastern Shore Richard A. Bernstein Endowment

Cannabinoid‐like compounds found in non‐cannabis plants exhibit antiseizure activity in genetic mouse models of drug‐resistant epilepsy

Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy

Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome

Arvanil, olvanil, AM 1172 and LY 2183240 (various cannabinoid CB1 receptor agonists) increase the threshold for maximal electroshock-induced seizures in mice

Huperzine A Provides Robust and Sustained Protection against Induced Seizures in Scn1a Mutant Mice

Cannabinoid Receptor 2 Agonist AM1241 Alleviates Epileptic Seizures and Epilepsy-Associated Depression Via Inhibiting Neuroinflammation in a Pilocarpine-Induced Chronic Epilepsy Mouse Model

Anti-seizure effects of JNJ-54175446 in the intra-amygdala kainic acid model of drug-resistant temporal lobe epilepsy in mice

Cannabidiol Exerts Anticonvulsant Effects Alone and in Combination with Δ9-THC through the 5-HT1A Receptor in the Neocortex of Mice

Magnolol, A Major Bioactive Constituent of the Bark of Magnolia Officinalis, Exerts Antiepileptic Effects Via the Gaba/Benzodiazepine Receptor Complex in Mice

Allosteric Modulation of Sigma-1 Receptors Elicits Anti-Seizure Activities.

Cannabinoid-mediated inhibition of recurrent excitatory circuitry in the dentate gyrus in a mouse model of temporal lobe epilepsy

The Drug Design and Discovery of Novel Enaminone Derivatives as Potential Anti-seizure Agents

Effects of WIN 55,212-2 mesylate on the anticonvulsant action of lamotrigine, oxcarbazepine, pregabalin and topiramate against maximal electroshock-induced seizures in mice

Beyond CBD: Inhibitory effects of lesser studied phytocannabinoids on human voltage-gated sodium channels

High concordance between hippocampal transcriptome of the mouse intra-amygdala kainic acid model and human temporal lobe epilepsy

Utilizing an acute hyperthermia‐induced seizure test and pharmacokinetic studies to establish optimal dosing regimens in a mouse model of Dravet syndrome

In silico investigation of potential phytoconstituents against ligand- and voltage-gated ion channels as antiepileptic agents

When Non-Promising Findings Also Go From Aquarium to Bedside: The Importance of Rigorous Preclinical Analyses of ASM Candidates

Molecular Pharmacology of Selective Na V 1.6 and Dual Na V 1.6/Na V 1.2 Channel Inhibitors that Suppress Excitatory Neuronal Activity Ex Vivo

Anticonvulsant Activity of Halogen-Substituted Cinnamic Acid Derivatives and Their Effects on Glycosylation of PTZ-Induced Chronic Epilepsy in Mice.

Cannabichromene from Full-Spectrum Hemp Extract Exerts Acute Anti-Seizure Effects Through Allosteric Activation of GABAA Receptors